Liver Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 1113
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: LCA49CCACC6EN
Leaflet:

Download PDF Leaflet

Liver Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Liver Cancer - Pipeline Review, H2 2015’, provides an overview of the Liver Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Liver Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Liver Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Liver Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Liver Cancer Overview
Therapeutics Development
Liver Cancer - Therapeutics under Development by Companies
Liver Cancer - Therapeutics under Investigation by Universities/Institutes
Liver Cancer - Pipeline Products Glance
Liver Cancer - Products under Development by Companies
Liver Cancer - Products under Investigation by Universities/Institutes
Liver Cancer - Companies Involved in Therapeutics Development
Liver Cancer - Therapeutics Assessment
Drug Profiles
Liver Cancer - Recent Pipeline Updates
Liver Cancer - Dormant Projects 1055
Liver Cancer - Discontinued Products 1070
Liver Cancer - Product Development Milestones 1074
Appendix 1081

LIST OF TABLES

Number of Products under Development for Liver Cancer, H2 2015
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Liver Cancer - Pipeline by 4SC AG, H2 2015
Liver Cancer - Pipeline by AB Science SA, H2 2015
Liver Cancer - Pipeline by AbbVie Inc., H2 2015
Liver Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015
Liver Cancer - Pipeline by ACROVIS Pharma AG, H2 2015
Liver Cancer - Pipeline by Adaptimmune Limited, H2 2015
Liver Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
Liver Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2015
Liver Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
Liver Cancer - Pipeline by Alfact Innovation, H2 2015
Liver Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by American Gene Technologies International Inc., H2 2015
Liver Cancer - Pipeline by Amgen Inc., H2 2015
Liver Cancer - Pipeline by AndroScience Corporation, H2 2015
Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H2 2015
Liver Cancer - Pipeline by Arbutus Biopharma Corporation, H2 2015
Liver Cancer - Pipeline by ArQule, Inc., H2 2015
Liver Cancer - Pipeline by Array BioPharma Inc., H2 2015
Liver Cancer - Pipeline by Arrowhead Research Corporation, H2 2015
Liver Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by AstraZeneca Plc, H2 2015
Liver Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Bayer AG, H2 2015
Liver Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
Liver Cancer - Pipeline by BioCancell Ltd, H2 2015
Liver Cancer - Pipeline by Biogazelle, H2 2015
Liver Cancer - Pipeline by Bioneer Corporation, H2 2015
Liver Cancer - Pipeline by BioStar Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Blueprint Medicines, H2 2015
Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Liver Cancer - Pipeline by Boston Biomedical, Inc., H2 2015
Liver Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Liver Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Liver Cancer - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Liver Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015
Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2015
Liver Cancer - Pipeline by Celgene Corporation, H2 2015
Liver Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Liver Cancer - Pipeline by Celsion Corporation, H2 2015
Liver Cancer - Pipeline by China Medical System Holdings Limited, H2 2015
Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Liver Cancer - Pipeline by Chroma Therapeutics Limited, H2 2015
Liver Cancer - Pipeline by CohBar, Inc., H2 2015
Liver Cancer - Pipeline by CrystalGenomics, Inc., H2 2015
Liver Cancer - Pipeline by CytRx Corporation, H2 2015
Liver Cancer - Pipeline by CZ BioMed Corp, H2 2015
Liver Cancer - Pipeline by Delcath Systems, Inc., H2 2015
Liver Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Digna Biotech, S.L., H2 2015
Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2015
Liver Cancer - Pipeline by e-Therapeutics Plc, H2 2015
Liver Cancer - Pipeline by Eisai Co., Ltd., H2 2015
Liver Cancer - Pipeline by Eli Lilly and Company, H2 2015
Liver Cancer - Pipeline by Endocyte, Inc., H2 2015
Liver Cancer - Pipeline by Erytech Pharma SA, H2 2015
Liver Cancer - Pipeline by Eureka Therapeutics, Inc., H2 2015
Liver Cancer - Pipeline by Exelixis, Inc., H2 2015
Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Liver Cancer - Pipeline by Genelux Corporation, H2 2015
Liver Cancer - Pipeline by Genoscience Pharma, H2 2015
Liver Cancer - Pipeline by GenSpera, Inc., H2 2015
Liver Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Liver Cancer - Pipeline by Golden Biotechnology Corp., H2 2015
Liver Cancer - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Liver Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015
Liver Cancer - Pipeline by Horizon Pharma Plc, H2 2015
Liver Cancer - Pipeline by Huperion Sarl, H2 2015
Liver Cancer - Pipeline by Immunicum AB, H2 2015
Liver Cancer - Pipeline by Immunitor, Inc., H2 2015
Liver Cancer - Pipeline by Immunomedics, Inc., H2 2015
Liver Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2015
Liver Cancer - Pipeline by Immuron Limited, H2 2015
Liver Cancer - Pipeline by IMPACT Therapeutics, Inc., H2 2015
Liver Cancer - Pipeline by In-Cell-Art S.A.S., H2 2015
Liver Cancer - Pipeline by Incanthera Ltd., H2 2015
Liver Cancer - Pipeline by Incuron, LLC, H2 2015
Liver Cancer - Pipeline by InteRNA Technologies B.V., H2 2015
Liver Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
Liver Cancer - Pipeline by Jenrin Discovery, Inc., H2 2015
Liver Cancer - Pipeline by Johnson & Johnson, H2 2015
Liver Cancer - Pipeline by JSK Therapeutics Inc., H2 2015
Liver Cancer - Pipeline by KAHR medical Ltd., H2 2015
Liver Cancer - Pipeline by Keystone Nano, Inc., H2 2015
Liver Cancer - Pipeline by Kite Pharma, Inc., H2 2015
Liver Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
Liver Cancer - Pipeline by Kowa Company, Ltd., H2 2015
Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2015
Liver Cancer - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by LivTech, Inc., H2 2015
Liver Cancer - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Liver Cancer - Pipeline by Lytix Biopharma AS, H2 2015
Liver Cancer - Pipeline by MaxCyte, Inc., H2 2015
Liver Cancer - Pipeline by MedImmune, LLC, H2 2015
Liver Cancer - Pipeline by Medivation, Inc., H2 2015
Liver Cancer - Pipeline by Medivir AB, H2 2015
Liver Cancer - Pipeline by Merck KGaA, H2 2015
Liver Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015
Liver Cancer - Pipeline by MolMed S.p.A., H2 2015
Liver Cancer - Pipeline by MultiCell Technologies, Inc., H2 2015
Liver Cancer - Pipeline by NeoPharm Co., Ltd., H2 2015
Liver Cancer - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Liver Cancer - Pipeline by NormOxys, Inc., H2 2015
Liver Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2015
Liver Cancer - Pipeline by Novartis AG, H2 2015
Liver Cancer - Pipeline by Nymox Pharmaceutical Corporation, H2 2015
Liver Cancer - Pipeline by Omeros Corporation, H2 2015
Liver Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015
Liver Cancer - Pipeline by Oncology Research International Limited, H2 2015
Liver Cancer - Pipeline by Oncolys BioPharma Inc., H2 2015
Liver Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by OncoTherapy Science, Inc., H2 2015
Liver Cancer - Pipeline by Oneness Biotech Co., Ltd., H2 2015
Liver Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Liver Cancer - Pipeline by Onxeo SA, H2 2015
Liver Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by OPKO Health, Inc., H2 2015
Liver Cancer - Pipeline by Orega Biotech SAS, H2 2015
Liver Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Liver Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Peptinov SAS, H2 2015
Liver Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Pfizer Inc., H2 2015
Liver Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Liver Cancer - Pipeline by PharmAbcine, Inc., H2 2015
Liver Cancer - Pipeline by PharmaEssentia Corporation, H2 2015
Liver Cancer - Pipeline by PhaseRx, Inc., H2 2015
Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2015
Liver Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Progen Pharmaceuticals Limited, H2 2015
Liver Cancer - Pipeline by ProMetic Life Sciences Inc., H2 2015
Liver Cancer - Pipeline by Provecs Medical GmbH, H2 2015
Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Qu Biologics Inc., H2 2015
Liver Cancer - Pipeline by Quimatryx, S.L., H2 2015
Liver Cancer - Pipeline by Raptor Pharmaceutical Corp., H2 2015
Liver Cancer - Pipeline by RedHill Biopharma Ltd., H2 2015
Liver Cancer - Pipeline by Regen BioPharma, Inc., H2 2015
Liver Cancer - Pipeline by Regulus Therapeutics Inc., H2 2015
Liver Cancer - Pipeline by Rigontec GmbH, H2 2015
Liver Cancer - Pipeline by Saronic Biotechnology, Inc., H2 2015
Liver Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Shenogen Pharma Group Ltd., H2 2015
Liver Cancer - Pipeline by Silence Therapeutics Plc, H2 2015
Liver Cancer - Pipeline by Sillajen Biotherapeutics, H2 2015
Liver Cancer - Pipeline by Sirnaomics, Inc., H2 2015
Liver Cancer - Pipeline by Synovo GmbH, H2 2015
Liver Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Liver Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2015
Liver Cancer - Pipeline by Targetome, H2 2015
Liver Cancer - Pipeline by Therapure Biopharma Inc., H2 2015
Liver Cancer - Pipeline by Theravectys SA, H2 2015
Liver Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Tiziana, H2 2015
Liver Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2015
Liver Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
Liver Cancer - Pipeline by Transgene Biotek Limited, H2 2015
Liver Cancer - Pipeline by Tumorend, LLC, H2 2015
Liver Cancer - Pipeline by VasGene Therapeutics, Inc., H2 2015
Liver Cancer - Pipeline by Vaxon Biotech, H2 2015
Liver Cancer - Pipeline by Vect-Horus S.A.S., H2 2015
Liver Cancer - Pipeline by Verlyx Pharma Inc., H2 2015
Liver Cancer - Pipeline by Vicus Therapeutics, LLC, H2 2015
Liver Cancer - Pipeline by Virttu Biologics Limited, H2 2015
Liver Cancer - Pipeline by Viventia Bio Inc., H2 2015
Liver Cancer - Pipeline by Welichem Biotech Inc., H2 2015
Liver Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Liver Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Liver Cancer - Dormant Projects, H2 2015 1087
Liver Cancer - Dormant Projects (Contd..1), H2 2015 1088
Liver Cancer - Dormant Projects (Contd..2), H2 2015 1089
Liver Cancer - Dormant Projects (Contd..3), H2 2015 1090
Liver Cancer - Dormant Projects (Contd..4), H2 2015 1091
Liver Cancer - Dormant Projects (Contd..5), H2 2015 1092
Liver Cancer - Dormant Projects (Contd..6), H2 2015 1093
Liver Cancer - Dormant Projects (Contd..7), H2 2015 1094
Liver Cancer - Dormant Projects (Contd..8), H2 2015 1095
Liver Cancer - Dormant Projects (Contd..9), H2 2015 1096
Liver Cancer - Dormant Projects (Contd..10), H2 2015 1097
Liver Cancer - Dormant Projects (Contd..11), H2 2015 1098
Liver Cancer - Dormant Projects (Contd..12), H2 2015 1099
Liver Cancer - Dormant Projects (Contd..13), H2 2015 1100
Liver Cancer - Dormant Projects (Contd..14), H2 2015 1101
Liver Cancer - Discontinued Products, H2 2015 1102
Liver Cancer - Discontinued Products (Contd..1), H2 2015 1103
Liver Cancer - Discontinued Products (Contd..2), H2 2015 1104
Liver Cancer - Discontinued Products (Contd..3), H2 2015 1105

LIST OF FIGURES

Number of Products under Development for Liver Cancer, H2 2015
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
ACROVIS Pharma AG
Adaptimmune Limited
Aduro BioTech, Inc.
Advanced Accelerator Applications SA
Advenchen Laboratories, LLC
Alfact Innovation
Alnylam Pharmaceuticals, Inc.
American Gene Technologies International Inc.
Amgen Inc.
AndroScience Corporation
APAvadis Biotechnologies Srl
Arbutus Biopharma Corporation
ArQule, Inc.
Array BioPharma Inc.
Arrowhead Research Corporation
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
Bio-Cancer Treatment International Limited
BioCancell Ltd
Biogazelle
Bioneer Corporation
BioStar Pharmaceuticals, Inc.
Blueprint Medicines
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Can-Fite BioPharma Ltd.
CASI Pharmaceuticals Inc.
CCRP Therapeutics GmbH
Celgene Corporation
Celldex Therapeutics, Inc.
Celsion Corporation
China Medical System Holdings Limited
Chipscreen Biosciences Ltd
Chroma Therapeutics Limited
CohBar, Inc.
CrystalGenomics, Inc.
CytRx Corporation
CZ BioMed Corp
Delcath Systems, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Double Bond Pharmaceutical International AB
e-Therapeutics Plc
Eisai Co., Ltd.
Eli Lilly and Company
Endocyte, Inc.
Erytech Pharma SA
Eureka Therapeutics, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genelux Corporation
Genoscience Pharma
GenSpera, Inc.
GlaxoSmithKline Plc
Golden Biotechnology Corp.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Horizon Pharma Plc
Huperion Sarl
Immunicum AB
Immunitor, Inc.
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Immuron Limited
IMPACT Therapeutics, Inc.
In-Cell-Art S.A.S.
Incanthera Ltd.
Incuron, LLC
InteRNA Technologies B.V.
Jasco Pharmaceuticals, LLC.
Jenrin Discovery, Inc.
Johnson & Johnson
JSK Therapeutics Inc.
KAHR medical Ltd.
Keystone Nano, Inc.
Kite Pharma, Inc.
Komipharm International Co., Ltd.
Kowa Company, Ltd.
Les Laboratoires Servier SAS
Ligand Pharmaceuticals, Inc.
LivTech, Inc.
Lixte Biotechnology Holdings, Inc.
Lytix Biopharma AS
MaxCyte, Inc.
MedImmune, LLC
Medivation, Inc.
Medivir AB
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
MolMed S.p.A.
MultiCell Technologies, Inc.
NeoPharm Co., Ltd.
Nimbus Therapeutics, LLC
NormOxys, Inc.
Northwest Biotherapeutics, Inc.
Novartis AG
Nymox Pharmaceutical Corporation
Omeros Corporation
Omnitura Therapeutics Inc.
Oncology Research International Limited
Oncolys BioPharma Inc.
OncoMed Pharmaceuticals, Inc.
OncoTherapy Science, Inc.
Oneness Biotech Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Onyx Pharmaceuticals, Inc.
OPKO Health, Inc.
Orega Biotech SAS
Otsuka Holdings Co., Ltd.
Panacea Pharmaceuticals, Inc.
Peptinov SAS
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
Pharma Mar, S.A.
PharmAbcine, Inc.
PharmaEssentia Corporation
PhaseRx, Inc.
Phosplatin Therapeutics LLC
Polaris Pharmaceuticals, Inc.
Progen Pharmaceuticals Limited
ProMetic Life Sciences Inc.
Provecs Medical GmbH
Provectus Biopharmaceuticals, Inc.
Qu Biologics Inc.
Quimatryx, S.L.
Raptor Pharmaceutical Corp.
RedHill Biopharma Ltd.
Regen BioPharma, Inc.
Regulus Therapeutics Inc.
Rigontec GmbH
Saronic Biotechnology, Inc.
Savoy Pharmaceuticals, Inc.
Shenogen Pharma Group Ltd.
Silence Therapeutics Plc
Sillajen Biotherapeutics
Sirnaomics, Inc.
Synovo GmbH
Synta Pharmaceuticals Corp.
Taiwan Liposome Company, Ltd.
Targetome
Therapure Biopharma Inc.
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tiziana
Toko Pharmaceutical Industries Co., Ltd.
TRACON Pharmaceuticals, Inc.
Transgene Biotek Limited
Tumorend, LLC
VasGene Therapeutics, Inc.
Vaxon Biotech
Vect-Horus S.A.S.
Verlyx Pharma Inc.
Vicus Therapeutics, LLC
Virttu Biologics Limited
Viventia Bio Inc.
Welichem Biotech Inc.
Zhejiang BetaPharma Co., Ltd.
Skip to top


Metastatic Liver Cancer - Pipeline Review, H2 2015 US$ 1,600.00 Oct, 2015 · 58 pages

Ask Your Question

Liver Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: